Kepivance (Swedish Orphan Biovitrum AB (publ))


Welcome to the PulseAid listing for the Kepivance drug offered from Swedish Orphan Biovitrum AB (publ). This Fibroblast Growth Factor 7 [Chemical/Ingredient],Increased Epithelial Proliferation [PE],Mucocutaneous Epithelial Cell Growth Factor [EPC] pharmaceutical is classified as a HUMAN PRESCRIPTION DRUG. Below, you can view details for this drug, such as its dosage form, route of delivery, start market/end market dates, and more. We have also randomly listed additional pharmaceuticals used in the same HUMAN PRESCRIPTION DRUG drug type category.
LABELER NAME / MANUFACTURER: Swedish Orphan Biovitrum AB (publ)
NON-PROPRIETARY NAME: palifermin
SUBSTANCE NAME: PALIFERMIN
TYPE: HUMAN PRESCRIPTION DRUG
PHARMA CLASS: Fibroblast Growth Factor 7 [Chemical/Ingredient],Increased Epithelial Proliferation [PE],Mucocutaneous Epithelial Cell Growth Factor [EPC]
ROUTE: INTRAVENOUS
DOSAGE FORM: INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION
MARKETING CATEGORY NAME: BLA
START MARKETING DATE: 2009-12-15
END MARKETING DATE: 0000-00-00


Kepivance HUMAN PRESCRIPTION DRUG Details:

Item DescriptionKepivance from Swedish Orphan Biovitrum AB (publ)
LABELER NAME: Swedish Orphan Biovitrum AB (publ)
DEA SCHEDULE:
ACTIVE STRENGTH: 6.25(mg/1.2mL)
START MARKETING DATE: 2009-12-15
END MARKETING DATE: 0000-00-00
PRODUCT ID: 66658-112_f5a852da-1b94-4f48-a4c9-7737dc814d03
PRODUCT NDC: 66658-112
APPLICATION NUMBER: BLA125103

Other PALIFERMIN Pharmaceutical Manufacturers / Labelers:

Manufacturer / LabelerProprietary Name
Swedish Orphan Biovitrum AB (publ)Kepivance